Two early phase clinical trials represent progress in Lassa fever vaccine and therapeutic development, including the first interventional treatment trial in decades.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Garry, R. F. Nat. Rev. Microbiol. 21, 87–96 (2023).
Ortiz, J. R. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04429-z (2026).
Erameh, C. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04402-w (2026).
Malkin, E. et al. N. Engl. J. Med. 393, 1807–1818 (2025).
Tschismarov, R. et al. Lancet 401, 1267–1276 (2023).
Salam, A. P. et al. PLoS Negl. Trop. Dis. 15, e0009522 (2021).
Korula, P. et al. Cochrane Database Syst. Rev. 2, CD015219 (2024).
Hayden, F. G. et al. J. Infect. Dis. 226, 1790–1799 (2022).
Salam, A. P. et al. PLoS Negl. Trop. Dis. 16, e0010289 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.J. has previously worked on rabies and Lassa vaccine candidates, but not on the candidates discussed in this piece, and declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Jenkin, D. Lassa fever countermeasures gather pace. Nat Med (2026). https://doi.org/10.1038/s41591-026-04478-4
Published:
Version of record:
DOI: https://doi.org/10.1038/s41591-026-04478-4